Adverse effects of androgen-deprivation therapy in prostate cancer and their management

BJU International

Volumn 115, Issue S5, 2015, Pages 3-13

  Rhee, Handoo ^a,b   Gunter, Jennifer H ^b   Heathcote, Peter ^a,b   Ho, Ken ^a   Stricker, Phillip ^c   Corcoran, Niall M ^d   Nelson, Colleen C ^b  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b TRANSLATIONAL RESEARCH INSTITUTE   (Australia)

^c GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d EPWORTH HEALTHCARE   (Australia)

Author keywords

adverse effect; androgen deprivation therapy; prostate cancer

Indexed keywords

ABIRATERONE; ACETYLSALICYLIC ACID; ADVERSE DRUG REACTION; ALENDRONIC ACID; ANTIANDROGEN; ANTINEOPLASTIC AGENT; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CYPROTERONE ACETATE; DENOSUMAB; DOCETAXEL; DRUG THERAPY; ENZALUTAMIDE; ESTRADIOL; GONADORELIN AGONIST; GONADORELIN DERIVATIVE; MEDROXYPROGESTERONE; MEGESTROL ACETATE; PREDNISOLONE; RISEDRONIC ACID; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN; VENLAFAXINE; VITAMIN D; ZOLEDRONIC ACID;

ACUTE KIDNEY FAILURE; ADVERSE OUTCOME; ANDROGEN DEPRIVATION THERAPY; ARTHRALGIA; ARTICLE; BACKACHE; CARDIOVASCULAR DISEASE; CASTRATION; CASTRATION RESISTANT PROSTATE CANCER; COGNITIVE DEFECT; DEPRESSION; DIABETES MELLITUS; DRUG MEGADOSE; DRUG THERAPY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ELDERLY CARE; EXERCISE; FATIGUE; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HEART ARRHYTHMIA; HEART FAILURE; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOCALCEMIA; INTERMITTENT ANDROGEN DEPRIVATION THERAPY; ISCHEMIC HEART DISEASE; JAW OSTEONECROSIS; LIBIDO DISORDER; LIVER TOXICITY; MALE; MASTALGIA; METABOLIC SYNDROME X; OBESITY; OSTEOPENIA; OSTEOPOROSIS; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL (TOPIC); PREVENTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; RISK REDUCTION; SAFETY; SEIZURE; SEXUAL DYSFUNCTION; SYSTEMATIC REVIEW; THERAPY; TREATMENT INDICATION; TREATMENT OUTCOME;

ADVERSE EFFECTS; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; DRUG THERAPY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; MALE; PREVENTION AND CONTROL; PROSTATIC NEOPLASMS; THERAPEUTIC USE; THERAPY;

EID: 84964266910     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12964     Document Type: Article

References (64)

1. Heidenreich A, Bastian PJ, Bellmunt J, et al. Guidelines on Prostate Cancer. Arnhem: European Association of Urology, 2012. Available at: http://www.uroweb.org/gls/pdf/08%20Prostate%20Cancer-LR%20March%2013th%202012.pdf. Accessed Fenruary 2015
2. Australian Cancer Network Management of Metastatic Prostate Cancer Working Group. Clinical Practice Guidelines for the Management of Locally Advanced and Metastatic Prostate Cancer. Sydney: Cancer Council Australia and Australian Cancer Network, 2010. Available at: https://www.andrologyaustralia.org/wp-content/uploads/FINAL-Advanced-Prostate-Cancer-Guidelines.pdf. Accessed February 2015
3. Pagliarulo V, Bracarda S, Eisenberger M, et al. Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol 2012; 61: 11-25
4. Mottet N, Bastian PJ, Bellmunt J, et al. Guidelines on prostate cancer 2014. Available at: http://www.uroweb.org/gls/pdf/09%20Prostate%20Cancer-LRLV2.pdf. Accessed February 2015
5. Studer UE, Whelan P, Wimpissinger F, et al. Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up. Eur Urol 2014; 66: 829-838
6. Wong YN, Freedland SJ, Egleston B, et al. The role of primary androgen deprivation therapy in localized prostate cancer. Eur Urol 2009; 56: 609-616
7. Lu-Yao GL, Albertsen PC, Moore DF, et al. Fifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancer. JAMA Intern Med 2014; 174: 1460-1467
8. Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014; 65: 467-479
9. National Comprehensive Cancer Network. NCCN Guidelines Version 1.2014 Prostate Cancer. 275 Commerce Drive, Suite 300, Fort Washington, PA: National Comprehensive Cancer Network, 2014. Available at: http://www.nccn.org/patients/guidelines/prostate-updates.aspx. Accessed February 2015
10. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR,. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001; 86: 724-731
11. Cheung AS, Pattison D, Bretherton I, et al. Cardiovascular risk and bone loss in men undergoing androgen deprivation therapy for non-metastatic prostate cancer: implementation of standardized management guidelines. Andrology 2013; 1: 583-589
12. Abu-Ghanem Y, Dhesi JK, Challacombe BJ,. The challenges of managing urological malignancy in the elderly. BJU Int 2014; 114: 12-15
13. Tsai HT, Penson DF, Makambi KH, et al. Efficacy of intermittent androgen deprivation therapy vs conventional continuous androgen deprivation therapy for advanced prostate cancer: a meta-analysis. Urology 2013; 82: 327-333
14. Wolff JM, Abrahamsson PA, Irani J, Calais da Silva F,. Is intermittent androgen deprivation therapy beneficial for advanced prostate cancer patients? BJU Int 2014; 114: 476-483
15. Crook JM, O'Callaghan CJ, Duncan G, et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 2012; 367: 895-903
16. de Leval J, Boca P, Yousef E, et al. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial. Clin Prostate Cancer 2002; 1: 163-171
17. Hussain M, Tangen CM, Berry DL, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 2013; 368: 1314-1325
18. Llorente MD, Burke M, Gregory GR, et al. Prostate cancer: a significant risk factor for late-life suicide. Am J Geriatr Psychiatry 2005; 13: 195-201
19. Green HJ, Pakenham KI, Headley BC, et al. Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial. BJU Int 2002; 90: 427-432
20. Green HJ, Pakenham KI, Headley BC, Gardiner RA,. Coping and health-related quality of life in men with prostate cancer randomly assigned to hormonal medication or close monitoring. Psychooncology 2002; 11: 401-414
21. Templeton H, Coates V,. Evaluation of an evidence-based education package for men with prostate cancer on hormonal manipulation therapy. Patient Educ Couns 2004; 55: 55-61
22. Green HJ, Pakenham KI, Headley BC, et al. Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trial. BJU Int 2004; 93: 975-979
23. Walker LM, Tran S, Robinson JW,. Luteinizing hormone-releasing hormone agonists: a quick reference for prevalence rates of potential adverse effects. Clin Genitourin Cancer 2013; 11: 375-384
24. Elliott S, Latini DM, Walker LM, Wassersug R, Robinson JW,. Androgen deprivation therapy for prostate cancer: recommendations to improve patient and partner quality of life. J Sex Med 2010; 7: 2996-3010
25. Viani GA, Bernardes da Silva LG, Stefano EJ,. Prevention of gynecomastia and breast pain caused by androgen deprivation therapy in prostate cancer: tamoxifen or radiotherapy? Int J Radiat Oncol Biol Phys 2012; 83: e519-524
26. Irani J, Salomon L, Oba R, Bouchard P, Mottet N,. Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial. Lancet Oncol 2010; 11: 147-154
27. Cormie P, Galvão DA, Spry N, et al. Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial. BJU Int 2015; 115: 256-266
28. Kim L, Rashid P,. 775 The Australian experience of the 'Man Plan' Exercise program for patients with prostate cancer on androgen deprivation therapy. J Urol 2013; 189 (Suppl.): e319
29. Galvao DA, Spry N, Denham J, et al. A multicentre year-long randomised controlled trial of exercise training targeting physical functioning in men with prostate cancer previously treated with androgen suppression and radiation from TROG 03.04 RADAR. Eur Urol 2014; 65: 856-864
30. Gardner JR, Livingston PM, Fraser SF,. Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: a systematic review. J Clin Oncol 2014; 32: 335-346
31. Alliance N-NVDP. Guidelines for the management of absolute cardiovascular disease risk: national stroke foundation 2012. Available at: http://strokefoundation.com.au/site/media/AbsoluteCVD-GL-webready.pdf. Accessed February 2015
32. Wadhwa VK, Weston R, Mistry R, Parr NJ,. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values. BJU Int 2009; 104: 800-805
33. Hamilton EJ, Ghasem-Zadeh A, Gianatti E, et al. Structural decay of bone microarchitecture in men with prostate cancer treated with androgen deprivation therapy. J Clin Endocrinol Metab 2010; 95: E456-463
34. Morote J, Morin JP, Orsola A, et al. Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. Urology 2007; 69: 500-504
35. Beebe-Dimmer JL, Cetin K, Shahinian V, et al. Timing of androgen deprivation therapy use and fracture risk among elderly men with prostate cancer in the United States. Pharmacoepidemiol Drug Saf 2012; 21: 70-78
36. Klotz LH, McNeill IY, Kebabdjian M, Zhang L, Chin JL,. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study. Eur Urol 2013; 63: 927-935
37. Smith MR, Eastham J, Gleason DM, et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003; 169: 2008-2012
38. Wirth M, Tammela T, Cicalese V, et al. Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS). Eur Urol 2015; 67: 482-491
39. Serpa Neto A, Tobias-Machado M, Esteves MA, et al. Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 2012; 15: 36-44
40. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377: 813-822
41. Smith MR, Egerdie B, Hernandez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009; 361: 745-755
42. Smith MR, Saad F, Coleman R, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 2012; 379: 39-46
43. Smith MR, Saad F, Oudard S, et al. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol 2013; 31: 3800-3806
44. Grossmann M, Hamilton EJ, Gilfillan C, et al. Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy. Med J Aust 2011; 194: 301-306
45. Keating NL, O'Malley AJ, Freedland SJ, Smith MR,. Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer? Eur Urol 2013; 64: 159-166
46. Levine GN, D'Amico AV, Berger P, et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation 2010; 121: 833-840
47. Jespersen CG, Norgaard M, Borre M,. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study. Eur Urol 2014; 65: 704-709
48. Nguyen PL,. Androgen-deprivation therapy and cardiovascular harm: let's not throw out the baby with the bathwater. Eur Urol 2014; 65: 710-712
49. World Health Organization. Obesity and overweight, Fact Sheet no. 311, 2012. Available at: http://www.who.int/mediacentre/factsheets/fs311/en/. Accessed February 2015
50. Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR,. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 2007; 99: 1516-1524
51. Smith MR, Finkelstein JS, McGovern FJ, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002; 87: 599-603
52. Kim HS, Freedland SJ,. Androgen deprivation therapy in prostate cancer: anticipated side-effects and their management. Curr Opin Support Palliat Care 2010; 4: 147-152
53. Potosky AL, Knopf K, Clegg LX, et al. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. J Clin Oncol 2001; 19: 3750-3757
54. Keating NL, O'Malley AJ, Smith MR,. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 24: 4448-4456
55. Smith MR, Lee H, Nathan DM,. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006; 91: 1305-1308
56. Keating NL, Liu PH, O'Malley AJ, Freedland SJ, Smith MR,. Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer. Eur Urol 2014; 65: 816-824
57. Gandaglia G, Sun M, Hu JC, et al. Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer. Eur Urol 2014; 66: 1125-1132
58. Lapi F, Azoulay L, Niazi MT, et al. Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer. JAMA 2013; 310: 289-296
59. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324: 787-790
60. Tombal B, Borre M, Rathenborg P, et al. Enzalutamide monotherpy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study. Lancet Oncol 2014; 15: 592-600
61. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005
62. Rathkopf DE, Smith MR, de Bono JS, et al. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol 2014; 66: 815-825
63. Shore ND, Karsh L, Gomella LG, Keane TE, Concepcion RS, Crawford D,. Avoiding obsolescence in advanced prostate cancer management: a guide for urologists. BJU Int 2015; 115: 188-197
64. Zhumkhawala AA, Gleason JM, Cheetham TC, et al. Osteoporosis management program decreases incidence of hip fracture in patients with prostate cancer receiving androgen deprivation therapy. Urology 2013; 81: 1010-1015